Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline Review, H1 2015

Description: Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline Review, H1 2015

Summary

This, ‘Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline Review, H1 2015’, provides an overview of the Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in -class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies
to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Contents:

List of Tables
List of Figures
Introduction

REPORT COVERAGE
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Overview
Therapeutics Development
Pipeline Products for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Overview
Pipeline Products for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Comparative Analysis
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Therapeutics under Development by Companies
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Therapeutics under Investigation by Universities/Institutes
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Products under Development by Companies
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Products under Investigation by Universities/Institutes
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Companies Involved in Therapeutics Development
Aeolus Pharmaceuticals, Inc.
Bolder Biotechnology, Inc.
Cantex Pharmaceuticals, Inc.
Cellerant Therapeutics, Inc.
Cleveland BioLabs, Inc.
Gamida Cell Ltd.
Humanetics Corporation
Meabco A/S
NeoStem, Inc.
Neumedicines Inc.
Onconova Therapeutics, Inc.
Piramal Enterprises Limited
Pluristem Therapeutics Inc.
Priaxon AG
ProCertus BioPharm Inc.
RDD Pharma Ltd.
RxBio, Inc.
Soligenix, Inc.
Terapio Corporation
Tonix Pharmaceuticals Holding Corp.
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
517-PXN - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AEOL-10171 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BBT-007 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BBT-015 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BBT-018 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BBT-045 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BCN-057 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BIO-300 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BP-C2 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CLT-009 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
EDL-2000 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
entolimod - Drug Profile
Product Description
Mechanism of Action
R&D Progress
EWA-001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GC-003 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GC-4403 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GC-4419 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
JP4-039 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NMIL-121 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
P-276 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Peptide to Agonize GHSR-1a for Sepsis, Acute Radiation Syndrome and Acute Ischemic Stroke - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PGX-100 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PLX-RAD - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PrC-210 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
reclisib sodium - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Recombinant Protein for Sepsis, Inflammatory bowel disease, Acute radiation syndrome and Ischemic organ injury - Drug Profile
Product Description
Mechanism of Action
R&D Progress
romyelocel-L - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RP-239X - Drug Profile
Product Description
Mechanism of Action
R&D Progress
rusalatide acetate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Rx-100 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RX-101 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SGX-201 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule for Radiation Proctitis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules for Radiation and Chemical Toxicity - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules for Radiation Toxicity - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Inhibit NO Synthase for Toxicology, Metabolic and Dermatology - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ST-7 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Stem Cell Therapy for Radiation Exposure - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SY-303A - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SY-513 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TPO-7630 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Recent Pipeline Updates
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Dormant Projects
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Product Development Milestones
Featured News & Press Releases
Jan 12, 2015: Cleveland BioLabs Receives Department of Defense Support to Further Development of Entolimod as a Medical Radiation Countermeasure
Sep 11, 2014: Cellerant Awarded $47.5 Million Under Existing U.S. Government Contract to Support Development of CLT-008
Sep 03, 2014: Cleveland BioLabs Announces Green Light to Submit Pre-Emergency Use Authorization Application for Entolimod
Apr 18, 2014: Neumedicines Publishes Clinical Data Demonstrating Safety and Hematopoietic and Immune Effects of HemaMax (rHuLL-12), a Radiation Medical Countermeasure
Apr 15, 2014: Neumedicines Announces Publication of Phase II-Equivalent Data Demonstrating the Survival Effect of HemaMax (rHuLL-12), a Radiation Medical Countermeasure
Feb 25, 2014: Humanetics Enters Into Cooperative Research and Development Agreement With the U.S. Army Medical Research Institute of Chemical Defense
Feb 03, 2014: U.S. National Institutes of Health to Commence New Study of Pluristem's PLX Cells for Acute Radiation Syndrome Treatment
Jan 23, 2014: Cleveland BioLabs Provides Update on Barda Development Proposal
Jan 09, 2014: Neumedicines to Feature HemaMax Study Results in Presentation at Biotech Showcase Conference
Dec 13, 2013: Neumedicines Presents HemaMax Clinical Data at the ASH Conference
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Number of Products under Development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), H1 2015
Number of Products under Development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Ordering:
Order Online - http://www.researchandmarkets.com/reports/3112075/
Order by Fax - using the form below
Order by Post - print the order form below and send to
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline Review, H1 2015
Web Address: http://www.researchandmarkets.com/reports/3112075/
Office Code: SCD21WLR

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th>Options</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) -</td>
<td>Single User:</td>
<td>USD 2000</td>
</tr>
<tr>
<td>Electronic (PDF) -</td>
<td>Site License:</td>
<td>USD 4000</td>
</tr>
<tr>
<td>Electronic (PDF) -</td>
<td>Enterprisewide:</td>
<td>USD 6000</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in **BLOCK CAPITALS**

<table>
<thead>
<tr>
<th>Title:</th>
<th>Mr ☐ Mrs ☐ Dr ☐ Miss ☐ Ms ☐ Prof ☐</th>
</tr>
</thead>
<tbody>
<tr>
<td>First Name:</td>
<td></td>
</tr>
<tr>
<td>Email Address: *</td>
<td></td>
</tr>
<tr>
<td>Job Title:</td>
<td></td>
</tr>
<tr>
<td>Organisation:</td>
<td></td>
</tr>
<tr>
<td>Address:</td>
<td></td>
</tr>
<tr>
<td>City:</td>
<td></td>
</tr>
<tr>
<td>Postal / Zip Code:</td>
<td></td>
</tr>
<tr>
<td>Country:</td>
<td></td>
</tr>
<tr>
<td>Phone Number:</td>
<td></td>
</tr>
<tr>
<td>Fax Number:</td>
<td></td>
</tr>
</tbody>
</table>

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: _____________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World